Revenue beat expectations, profit guidance was raised, yet adjusted EPS fell year over year—so is Merck’s third-quarter report a beat or a miss?
Merck (U.S.) announced its 2026 third-quarter earnings before the U.S. market open on $MRK 10-10-29: revenue was $18.085 billion, up 5% year over year (up 4% excluding exchange-rate effects), above market expectations of $17.31 billion to $17.33 billion; adjusted EPS was $2.49, above expectations of $2.08 to $2.12, but down 3% from $2.58 in the same period last year; on a GAAP basis, net income was $5.065 billion and EPS was $2.04, both down 12% year over year.
By segment: combined sales of Keytruda and the new formulation Qlex reached $8.601 billion, up 6% year over year, including $830 million from the subcutaneous Qlex version in the quarter; Winrevair sales were $694 million, up 93%; animal health revenue was $1.676 billion, up 4%. The company also raised full-year guidance: revenue was narrowed to $66.8 billion to $67.3 billion, and adjusted EPS guidance was raised to $2.77 to $2.82 (from $2.66 to $2.76 previously), including a one-time expense of $0.12 per share related to the global licensing agreement with SciBrunch. Pre-market shares rose about 2.2% to $143.99.
How to read it: this is a report with “double beats on the headline, but the details need scrutiny.” On one hand, the Keytruda core business remained stable, Qlex volume exceeded expectations, and guidance was raised, giving the market reason to keep pricing in growth; on the other hand, the company itself acknowledged that about $550 million of growth came from the timing of customer advance purchases, accounting for roughly 70% of this quarter’s year-over-year revenue increase—that is demand pulled forward, not new demand, so whether it can be sustained in Q4 is an open question. Add to that the fact that Keytruda patents start expiring in stages from 2028, and the real test is how quickly Qlex can take over. If Q4 sees continued Qlex volume growth and no demand hangover from advance buying, guidance could still be revised upward; if Q4 growth slows and generic competition starts to emerge earlier than expected, this double beat will simply have shifted tomorrow’s growth into today. Don’t chase the first opening move—wait for the Q4 purchasing pace and Qlex conversion rate before deciding the direction.
Data as of: 2026-10-29 14:49 UTC
For information sharing only, not investment advice.
Merck (U.S.) announced its 2026 third-quarter earnings before the U.S. market open on $MRK 10-10-29: revenue was $18.085 billion, up 5% year over year (up 4% excluding exchange-rate effects), above market expectations of $17.31 billion to $17.33 billion; adjusted EPS was $2.49, above expectations of $2.08 to $2.12, but down 3% from $2.58 in the same period last year; on a GAAP basis, net income was $5.065 billion and EPS was $2.04, both down 12% year over year.
By segment: combined sales of Keytruda and the new formulation Qlex reached $8.601 billion, up 6% year over year, including $830 million from the subcutaneous Qlex version in the quarter; Winrevair sales were $694 million, up 93%; animal health revenue was $1.676 billion, up 4%. The company also raised full-year guidance: revenue was narrowed to $66.8 billion to $67.3 billion, and adjusted EPS guidance was raised to $2.77 to $2.82 (from $2.66 to $2.76 previously), including a one-time expense of $0.12 per share related to the global licensing agreement with SciBrunch. Pre-market shares rose about 2.2% to $143.99.
How to read it: this is a report with “double beats on the headline, but the details need scrutiny.” On one hand, the Keytruda core business remained stable, Qlex volume exceeded expectations, and guidance was raised, giving the market reason to keep pricing in growth; on the other hand, the company itself acknowledged that about $550 million of growth came from the timing of customer advance purchases, accounting for roughly 70% of this quarter’s year-over-year revenue increase—that is demand pulled forward, not new demand, so whether it can be sustained in Q4 is an open question. Add to that the fact that Keytruda patents start expiring in stages from 2028, and the real test is how quickly Qlex can take over. If Q4 sees continued Qlex volume growth and no demand hangover from advance buying, guidance could still be revised upward; if Q4 growth slows and generic competition starts to emerge earlier than expected, this double beat will simply have shifted tomorrow’s growth into today. Don’t chase the first opening move—wait for the Q4 purchasing pace and Qlex conversion rate before deciding the direction.
Data as of: 2026-10-29 14:49 UTC
For information sharing only, not investment advice.
